Sofie Biosciences

Sofie Biosciences receives $1M Phase II SBIR grant from the DOE.

CULVER CITY, Calif., July 11, 2012 — Sofie Biosciences, Inc., a molecular imaging company offering a comprehensive range of products from preclinical imaging systems to novel diagnostic PET imaging probes, announced today that the Department of Energy has awarded the company a grant under the Small Business Innovation Research (SBIR) program. This Phase II award, for approximately $1M, will support the development of a microscale technology for rapid, easy synthesis of PET probes.

Presently, scientists and clinicians must accept the limitations of the centralized radiopharmacy model of PET probe production and distribution, where a limited number of probes are available from radiochemistry cores or, more often, commercial radiopharmacies that provide an even smaller menu from which to choose. The end result is that the average investigator is restricted to a handful of PET probes, namely [18F]FDG, [18F]NaF, and occasionally [18F]FLT, leaving the 1,600+ probes that have been synthesized just out of reach, thus drastically limiting the translational power of PET to a few disciplines and applications.

“We are extremely pleased to be recognized with this highly competitive award from DOE,” said Patrick W. Phelps, President and CEO. “It’s an important step to further the development of a proprietary, game-changing technology that will provides researchers and clinicians with a first-generation device for the production of one-pot PET probes.”

These funds will be invested alongside Sofie resources to help broaden access to novel PET probes to answer fundamental biological questions in disease. “Winning this grant from DOE both supports and accelerates our efforts to bring radiochemistry-on-chip to market, a critical step in Sofie’s vision of creating a transformative technology of an affordable, compact, easy-to-use system for the on-demand production of PET probes,” commented Dr. Melissa Esterby, Director, Technology Development, who will be the Principal Investigator working in close collaboration with co-PI and inventor Dr. R. Michael van Dam at UCLA.

Posted: Tuesday October 30, 2012

Sofie Biosciences and OsiriX announce the release of open-source translational image analysis software.

CULVER CITY, CA - Sofie Biosciences, a molecular imaging company focused on empowering people with new PET technologies, announces a partnership with the image analysis software group the OsiriX Foundation. Under the agreement, researchers and clinicians will now be able to review preclinical and clinical image data on one comprehensive analysis platform across multiple modalities.

Recently, Sofie Biosciences introduced GENISYS™, the first high-performance, benchtop, cost-effective small animal PET system. GENISYS offers a PET imaging solution to complement existing preclinical experiments. By delivering turnkey operation and streamlined workflow, GENISYS uncouples researchers from their dependency on others, allowing for study design and data output on their terms. With the integration of GENISYS and OsiriX, researchers and clinicians now have a valuable translational image analysis tool.

“Sofie Biosciences believes in the mission of OsiriX to lead a paradigm shift in software development with a trend toward sharing and cooperation in the development of imaging software applications,” said Patrick Phelps, President & CEO, Sofie Biosciences. “Sofie worked closely with the OsiriX team to deliver a preclinical tool kit to enhance their existing suite of advanced analysis features. Together, GENISYS and OsiriX address the unmet needs of researchers and clinicians in molecular imaging. This is an important first step in building a community of developers around GENISYS.”

Posted: Friday September 3, 2010